Barclays Adjusts Price Target on Centene to $90 From $104, Maintains Overweight Rating
Navigating 11 Analyst Ratings For Centene
Centene Analyst Ratings
Centene Analyst Ratings
Stephens Adjusts Price Target on Centene to $77 From $83
Centene Analyst Ratings
What 11 Analyst Ratings Have To Say About Centene
Oppenheimer Remains a Buy on Centene (CNC)
Analysts Offer Insights on Healthcare Companies: Centene (CNC), Zimmer Biomet Holdings (ZBH) and Madrigal Pharmaceuticals (MDGL)
Centene Analyst Ratings
Baird Initiates Coverage On Centene With Neutral Rating, Announces Price Target of $83
Centene Analyst Ratings
Centene Analyst Ratings
Jefferies Adjusts Price Target on Centene to $90 From $94
Centene Analyst Ratings
Oppenheimer Sticks to Its Buy Rating for Centene (CNC)
Truist Financial Remains a Buy on Centene (CNC)
Centene's Resilience Amid Medicaid Pressures Justifies Buy Rating and $93 Price Target
Goldman Sachs Sticks to Its Hold Rating for Centene (CNC)
Centene Analyst Ratings